Key statistics
On Friday, Iovance Biotherapeutics Inc (0JDK:LSE) closed at 2.58, 64.33% above the 52 week low of 1.57 set on May 19, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | -- |
|---|---|
| High | 2.58 |
| Low | 2.58 |
| Bid | -- |
| Offer | -- |
| Previous close | 2.54 |
| Average volume | 90.68k |
|---|---|
| Shares outstanding | 396.97m |
| Free float | 393.11m |
| P/E (TTM) | -- |
| Market cap | 1.02bn USD |
| EPS (TTM) | -1.20 USD |
Data delayed at least 20 minutes, as of Feb 13 2026 19:09 GMT.
More ▼
Announcements
- Iovance Biotherapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Updates on Tuesday, February 24, 2026
- Best-in-Class Real-World Data Support Early Amtagvi® Treatment in Advanced Melanoma
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
- Iovance Biotherapeutics Highlights Business Achievements, Pipeline Milestones, and Third Quarter 2025 Results
- Iovance Biotherapeutics Reports Potential Best-in-Class Clinical Data for Lifileucel TIL Cell Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC)
- Iovance Biotherapeutics to Host Third Quarter 2025 Financial Results and Corporate Updates Webcast on Thursday, November 6, 2025
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
More ▼
